From the Canadian Press:
A Canadian pharmaceutical company is touting the benefits of a drug to treat advanced breast cancer.
Results of two studies have been released at a cancer conference in Chicago on the effectiveness of Tykerb, made by Mississauga, Ont.-based GlaxoSmithKline.
Tykerb tablets are meant to be a once-daily oral treatment for women with HER-2 positive breast cancer.
They claim Tykerb reduced brain tumour volume in some women whose breast cancer had spread, and, when used in combination with another drug, paclitaxel, can improve progression-free survival times for women with HER2-positive advanced breast cancer. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment